Compare Alphabet Inc Class A (GOOGL) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Alphabet Inc Class A trades at $342.18 (market cap $4.30T), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Alphabet Inc Class A is far larger — about 4419.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 86 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GOOGL | MRVI | |
|---|---|---|
Market Cap | $4.30T | $972.90M |
Volume | 22,270,289 | 4,325,710 |
Sector | Media | Health |
52-Week High | $402.62 | $9.00 |
52-Week Low | $250.46 | $2.83 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $4.19T | $1.08B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $347.64, down 1.44% today, but maintains strong technical support near $344-$350. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving a 54.77% net margin. Recent earnings beats and strong analyst consensus support the bullish outlook, with 87% of analysts rating it a Buy. Technical indicators show bullish moving averages but overbought RSI conditions.
Alphabet presents a compelling investment case with strong AI-driven growth, consistent earnings outperformance, and dominant market positioning. Key risks include regulatory scrutiny, competitive pressures in AI, and market volatility. With a consensus price target of $430.96 representing 24% upside potential, the stock offers attractive long-term value despite short-term technical overbought conditions.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
